

## Newsletter #7

07 October 2021

**Thanks to the PsoProtect, BSPD, and ESPD groups for their collaboration**

<b>Total number of cases reported</b>				<b>66</b>	
<b>Countries that assessed children, n</b>					
France	44	Italy	3	United Kingdom	1
Poland	9	India	3		
Russia	4	Portugal	2		
<b>Children</b>					
Girls / boys				26 / 40	
Age (mean ± SD)				12.4 ± 3.7 y	
<b>Psoriasis before COVID-19</b>					
Age of onset of psoriasis (mean ± SD)				6.4 ± 3.9 y	
Plaque psoriasis				44	
Nail psoriasis				34	
Psoriasis arthritis				3	
<b>COVID-19</b>					
Confirmed / suspected				58 / 8	
N° of COVID-19 / child					
1				64	
2				1	
Symptoms, yes				43	
Hospitalization / oxygen therapy				0 / 0	
Long-Covid				1	
<b>Since COVID-19 onset, the psoriasis has</b>					
Improved				0	
Worsened, with same psoriasis phenotype				6	
Worsened, phenotype changed				0	
Remained same				50	
Psoriasis de novo				3	
No information				7	
<b>Systemic medication for psoriasis at time of onset of COVID-19</b>					
Phototherapy	4	Cyclosporine	1	Ustekinumab	8
Methotrexate	7	Adalimumab	5	Risankizumab	1
Acitretin	4	Etanercept	4		

**You can include children with psoriasis and COVID-19 on:**

<https://docs.google.com/forms/d/e/1FAIpQLSeWcMLUXAfnx4ky8CEUILWa7veJmHb0FthGKuudaQDwbCfNQ/viewform?vc=0&c=0&w=1&flr=0>

**Website: [www.sfdermato.org/site/chi-psocov.html](http://www.sfdermato.org/site/chi-psocov.html)**